FUNDS UTILIZATION DETAILS

A brief justification for deploying funds raised through investors to further enhance our
pharmaceutical manufacturing establishment, which has been operational since 2004. We
are proud to operate a state-of-the-art WHO GMP approved plant specializing in the
production of tablets, syrups, capsules, and ointments. Our business encompasses both
international exports to African, Latin American, and Southeast Asian markets and
domestic operations, including supplies to various state governments in India through
tenders.
,

We plan to allocate 70% of the funds received from investors towards the expansion of our
existing business. This allocation will be dedicated to three key areas:

1. Upgrading Manufacturing Facilities: A significant portion of the funds will be invested

in upgrading our current manufacturing facility. These upgrades will focus on enhancing
both the quality and quantity of our pharmaceutical production. By implementing the

latest technologies and manufacturing processes, we aim to improve production

efficiency and maintain the highest product quality standards.
2. Acquiring New Manufacturing Facilities: We intend to use a portion of the funds to

acquire new manufacturing facilities, allowing us to diversify and expand into new
pharmaceutical categories. This strategic move will not only increase our overall

production capacity but also enable us to tap into emerging markets and product
segments.

3. Establishing A Result – Oriented Marketing Network: Developing an effective

marketing network is pivotal to the growth of our pharmaceutical business. We plan to
use funds to establish a robust and result-oriented marketing network that will
encompass various regions. This will include building a dedicated and skilled sales and

marketing team to promote our products and expand our market reach.
The remaining 30% of the funds will be retained for working capital requirements. A strong and
flexible working capital is essential to achieving our expansion goals, ensuring the smooth
operation of our manufacturing facilities, and addressing any unexpected financial demands.

In summary, deploying funds for our pharmaceutical manufacturing establishment will be

instrumental in taking our business to the next level. With strategic investments in upgrading
existing facilities, acquiring new ones, and establishing an effective marketing network, we are
confident that we will achieve our goals of increasing production output, expanding into new
markets, and maintaining our reputation for high-quality pharmaceutical products. The
allocation of 30% towards working capital ensures that we have the financial flexibility to
support these growth initiatives effectively.

I would like to provide a comprehensive overview of the remarkable growth our pharmaceutical
manufacturing establishment has experienced in the last three financial years and our ambitious
projections for the year 2023-2024.

Growth in the last three financial Years:

As of the financial year 2020-2021, our annual turnover was 19 crores. This figure increased
significantly over the subsequent years:

1. In the financial year 2021-2022, we achieved a substantial revenue growth, pushing our
turnover to 29 crores.

2. In the financial year 2022-2023, our revenue further surged to an impressive 46 crores.
Graph :

Rs. In Millions
1000

900

800

700

600
Sales in Rs.

500

400

300

200

100

0
2021 2022 2023 2024
Year

Future Projections for 2023 – 2024:

Building on this impressive track record, we have set ambitious projections for the financial year
2023-2024. We aim to achieve a turnover of 90 crores. This projection reflects our unwavering

commitment to excellence, strategic expansion, and market penetration.

Factor Contributing to Growth:

Our consistent growth can be attributed to several key factors:
1. Quality Assurance: We have maintained a strong focus on adhering to WHO GMP
standards and delivering products of the highest quality.

2. Diversification: Our expansion into new pharmaceutical categories has broadened our
product range, enabling us to cater to a wider market and respond to changing

consumer demands.
3. International Expansion: Our exports to African, Latin American, and Southeast Asian

markets have opened up new revenue streams and enhanced our global presence.
4. Domestic Tenders: Our ability to secure government tenders in India has provided a

stable source of income and contributed to our growth.

Growth Strategy:
To ensure that we continue on this upward trajectory, we plan to allocate funds, with a
majority (70%) dedicated to the following strategies:
1. Upgrading Existing Facilities: This investment will allow us to improve production

efficiency and maintain high-quality standards.

2. Acquiring New Facilities: Diversifying into new pharmaceutical categories will increase

our production capacity and expand our market reach.

3. Result Oriented Marketing Network: A robust marketing network will help us

effectively promote our products and grow our market presence.

The remaining 30% of the funds will be retained for working capital, ensuring that we have the
necessary financial flexibility to support these expansion initiatives.

Our growth journey is not just a testament to our dedication to quality and innovation but also

to the trust of our customers and the relentless efforts of our team. We are excited about the
future and look forward to achieving our projected milestone of 90 crores in the financial year

2023-2024.
Please feel free to reach out if you have any questions or require additional information.

We look forward to your support in this endeavour and welcome any further discussions
regarding our expansion plans.

Sincerely,
Sanjay B Surana
Director
+91 9892998209
Maxwell Life Science Pvt Ltd
Factory: T-53 & T-81, MIDC, Tarapur, Dist. Palghar, Boisar - 401506, Maharashtra, India.
Corporate Office: 05, 2nd Floor, Target Mall, Chandavarkar Road, Borivali (West). Mumbai 400092

Web : www.mlspl.in
Email : info@mlspl.in